arrow_back Back to App

Tardive Dyskinesia Awareness Week: Supporting Individuals with Movement Disorders

The U.S. House of Representatives supports designating a week for Tardive Dyskinesia Awareness. This aims to increase public and medical community knowledge about this involuntary movement disorder, often linked to long-term use of certain medications for mental or gastrointestinal conditions. Greater awareness can lead to earlier diagnosis and treatment, improving patients' quality of life.
Key points
Designation of Tardive Dyskinesia Awareness Week (May 5-11, 2024) aims to educate the public and medical community.
Tardive Dyskinesia (TD) involves uncontrollable body movements, often a side effect of long-term use of certain medications, e.g., for mental illnesses.
Increased awareness is crucial for earlier diagnosis and treatment, potentially improving the lives of an estimated 600,000 people in the U.S. affected by TD.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_HRES_1200
Sponsor: Rep. Peters, Scott H. [D-CA-50]
Process start date: 2024-05-06
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Expressing support for the designation of the week of May 5, 2024, through May 11, 2024, as "Tardive Dyskinesia Awareness Week".

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_HRES_1200.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2024-05-06.

What are the main provisions?

Key points include:

  • Designation of Tardive Dyskinesia Awareness Week (May 5-11, 2024) aims to educate the public and medical community.
  • Tardive Dyskinesia (TD) involves uncontrollable body movements, often a side effect of long-term use of certain medications, e.g., for mental illnesses.
  • Increased awareness is crucial for earlier diagnosis and treatment, potentially improving the lives of an estimated 600,000 people in the U.S. affected by TD.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Peters, Scott H. [D-CA-50].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-24.

CATEGORIES

Health